NCT07561528

Brief Summary

Purpose: This study aims to evaluate the effectiveness of an accelerated intermittent Theta Burst Stimulation (iTBS) protocol-a non-invasive brain stimulation technique-targeted at the dorsomedial prefrontal cortex (dmPFC) and anterior cingulate cortex (ACC) in patients with treatment-resistant Obsessive-Compulsive Disorder (OCD). Additionally, the study seeks to identify electrophysiological biomarkers (such as EEG microstates and heart rate variability) that may predict which patients are most likely to benefit from the treatment. Methodology: The study will include 30 patients aged 18-65 diagnosed with OCD according to DSM-5 criteria who have not responded sufficiently to standard treatments. Participants will undergo an intensive 7-day treatment program consisting of 4 iTBS sessions per day (totaling 28 sessions). Clinical symptoms will be assessed before and after the treatment using standardized scales, including the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), Hamilton Depression Rating Scale (HAM-D), and Hamilton Anxiety Rating Scale (HAM-A). Resting-state EEG measurements and heart rate data will be recorded during and after the sessions to analyze physiological changes. Goal: The findings are expected to contribute to the development of personalized neuromodulation protocols and help identify predictors of treatment response for OCD patients.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for phase_4

Timeline
12mo left

Started Feb 2026

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress21%
Feb 2026May 2027

Study Start

First participant enrolled

February 1, 2026

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

April 26, 2026

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 1, 2026

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2027

Expected
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2027

Last Updated

May 1, 2026

Status Verified

April 1, 2026

Enrollment Period

1 year

First QC Date

April 26, 2026

Last Update Submit

April 26, 2026

Conditions

Outcome Measures

Primary Outcomes (2)

  • Yale-Brown Obsessive-Compulsive Scale

    Change from baseline in clinical scales at the end of the 7-day treatment and at follow-up points (1, 3, and 6 months post-treatment)"

  • Analysis of microstate EEG

    Change from baseline at the end of the 7-day treatment and at follow-up points

Study Arms (1)

TMS Treatment Arm

ACTIVE COMPARATOR
Device: iTBS TMS

Interventions

iTBS TMSDEVICE

Accelerated intermittent Theta Burst Stimulation (iTBS) will be delivered using a MagVenture MagPro R30 stimulator with a Cool D-B80 double cone coil. The stimulation is targeted at the dorsomedial prefrontal cortex (dmPFC) and anterior cingulate cortex (ACC), specifically 25.8% anterior of the nasion-inion distance. The treatment will be applied at 100% of the motor threshold, which is determined via the Extensor Hallucis Longus muscle. The protocol consists of an intensive 7-day program with 4 sessions per day, totaling 28 sessions. Each session delivers 1,800 pulses and lasts approximately 9 minutes. Patients will continue their stable dose of Selective Serotonin Reuptake Inhibitors (SSRIs) throughout the study.

TMS Treatment Arm

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Being between 18 and 65 years of age.
  • Being diagnosed with Obsessive-Compulsive Disorder (OCD) according to DSM-5 criteria.
  • Non-responsiveness to at least one Selective Serotonin Reuptake Inhibitor (SSRI) treatment at an adequate dose and duration.
  • Having a Y-BOCS score of ≥20 following the initial evaluation.
  • Receiving maintenance treatment with a therapeutic dose of SSRI for at least 2 months.
  • No change in the current SSRI or other medications within the last 2 months and a commitment to maintaining stable doses throughout the study.
  • Providing informed consent and having no contraindications for TMS

You may not qualify if:

  • Severe neurological disorders (e.g., brain tumor, progressive neurodegenerative diseases).
  • Any condition associated with increased seizure risk (e.g., epilepsy, history of severe head trauma).
  • History of cochlear implants, metal implants in the head and neck area, cardiac pacemakers, deep brain stimulation, or vagus nerve stimulation.
  • History of neurosurgical intervention.
  • General contraindications for Transcranial Magnetic Stimulation therapy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cerrahpaşa Tıp Fakültesi Prof. Dr. Murat Dilmener Hastanesi

Istanbul, Bakirkoy, 34153, Turkey (Türkiye)

RECRUITING

Related Publications (1)

  • McGirr A, Cole J, Patten SB, Adams B. Intermittent Theta Burst Stimulation With Adjunctive D-Cycloserine for Obsessive-Compulsive Disorder: A Randomized Clinical Trial. Am J Psychiatry. 2025 Mar 1;182(3):307-311. doi: 10.1176/appi.ajp.20240181. Epub 2025 Feb 19. No abstract available.

    PMID: 39967412BACKGROUND

MeSH Terms

Conditions

Compulsive Personality Disorder

Condition Hierarchy (Ancestors)

Personality DisordersMental Disorders

Central Study Contacts

Sarp Yoldas, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

April 26, 2026

First Posted

May 1, 2026

Study Start

February 1, 2026

Primary Completion (Estimated)

February 1, 2027

Study Completion (Estimated)

May 1, 2027

Last Updated

May 1, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will share
Shared Documents
STUDY PROTOCOL

Locations